The role of testing for BRCA1 and BRCA2 mutations in cancer prevention

JAMA Internal Medicine

Volumn 174, Issue 7, 2014, Pages 1023-1024

  McCarthy, Anne Marie ^a   Armstrong, Katrina ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; RALOXIFENE; TAMOXIFEN;

ASHKENAZI JEW; BLOOD CLOT; BODY IMAGE; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CANCER SUSCEPTIBILITY; CEREBROVASCULAR ACCIDENT; DNA REPAIR; ECHOGRAPHY; FAMILY HISTORY; FEMALE FERTILITY; GENE MUTATION; GENE SEQUENCE; GENETIC COUNSELING; GENETIC SCREENING; GENETIC VARIABILITY; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HIGH RISK POPULATION; HUMAN; MAMMOGRAPHY; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PHYSICIAN; PRIORITY JOURNAL; RISK MANAGEMENT; RISK REDUCTION; SHORT SURVEY; TUMOR GENE; TUMOR SUPPRESSOR GENE; UTERUS CANCER;

BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; MASS SCREENING; MUTATION;

EID: 84904120887     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2014.1322     Document Type: Short Survey

References (9)

1. Jolie A. My medical choice. The New York Times. May 14, 2013; Opinion. http://www.nytimes.com/2013/05/14/opinion/my-medical-choice.html. Accessed March 25, 2014.
2. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25(11):1329-1333. (Pubitemid 46706879)
3. Daly MB, Axilbund JE, Buys S, et al National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw. 2010;8(5):562-594.
4. Nelson HD, Pappas M, Zakher B, Mitchell JP, Okinaka-Hu L, Fu R. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the US Preventive Services Task Force recommendation. Ann Intern Med. 2014;160(4):255-266.
5. Sherkow JS, Greely HT. The future of gene patents and the implications for medicine. JAMA Intern Med. 2013;173(17):1569-1570.
6. Rabin RC. Push to test for cancer gene sets up a dilemma in Israel. The New York Times. November 27, 2013; A1.
7. Kauff ND, Perez-Segura P, Robson ME, et al. Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families. J Med Genet. 2002;39(8):611-614. (Pubitemid 34864569)
8. Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol. 2002;20(6):1480-1490. (Pubitemid 34260526)
9. McCarthy AM, Bristol M, Fredricks T, et al. Are physician recommendations for BRCA1/2 testing in patients with breast cancer appropriate? a population-based study. Cancer. 2013;119(20):3596-3603.